How ESE is Funded
The following funding model has been deemed suitable for participating in EMA activities, acting in the interests of European patients, consumers and healthcare professionals. This evaluation was completed with reference to ESE funding for the 2023 financial year.
ESE is funded through a number of industry and non-industry sources:
- Membership – individual
- Membership – Corporate – See all our Corporate members
- Revenue generated by ESE owned journal ‘European Journal of Endocrinology’
- Revenue from industry into ECE and other educational programmes, principally through support of satellite sessions and exhibition stands and unrestricted educational grants in support of postgraduate education
- Of the revenue into ESE in the 2023 accounts 33.8% was provided by industry.
- The highest contribution from a single company represented 16.5% of the industry revenue and 5.6% of ESE revenue overall.
The list of all industry and non-industry revenue sources in 2023 are listed below.
- Ace Pharmaceuticals BV
- Addisons Disease Self Help Group (joint with CAH)
- Alexion
- Amolyt Pharma
- AndroLabs
- Ascendis Pharma
- Ashfield MedComms GmbH
- BridgeBio
- Clarius Mobile Health
- Clinical Endocrinology Trust
- COGNITE
- Corcept Therapeutics
- Crinetics Pharmaceuticals Inc.
- DMR Kongress Org.
- Endocrine Society
- Endo-ERN
- Global Business Travel Spain SL
- Horizon Therapeutics
- HRA Pharma Rare Diseases
- Inozyme Pharma
- International Prader-Willi Syndrome Organisation (IPWSO)
- Ipsen
- Maxelance Tur. Org. Rek. Ajans Hiz. A.
- Neurocrine Biosciences/Diurnal Ltd
- Novo Nordisk Health Care AG
- Outline Event Services Ltd
- Oxford University Press
- Pfizer Ltd
- Pharmanovia
- Privilege Service Sagl
- Rapier Design Limited
- Recordati Rare Diseases AG
- Rhythm Pharmaceuticals
- Takeda Pharmaceuticals International AG
- Thyroid Federation International
- Uni Pharma Kleon Tsetis
- VIAD Service Companies Ltd t/a Spiro
- World Alliance of Pituitary Organizations (WAPO)
